Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Drug DiscoveryVaccinesCRO

PUBLISHER: Visiongain | PRODUCT CODE: 1919594

Cover Image

PUBLISHER: Visiongain | PRODUCT CODE: 1919594

Vaccine Contract Manufacturing Market Report 2026-2036

PUBLISHED:
PAGES: 314 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 6003
PDF (Team License - Up to 6 Users)
USD 7107
PDF (Site License)
USD 8349
PDF (Enterprise License - Includes Free Datasets)
USD 10550.10

Add to Cart

Description

Table of Contents

List of Tables

The global Vaccine Contract Manufacturing market is projected to grow at a CAGR of 10.9% by 2036.

The Vaccine Contract Manufacturing Market Report 2026-2036 (Including Impact of U.S. Trade Tariffs): This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Outsourcing as a Core Structural Model in Vaccine Contract Manufacturing

Vaccine manufacturing is increasingly being treated as a strategic capability that does not necessarily need to be owned and operated in-house. Developers are re-evaluating the long-term economics of maintaining specialised vaccine production facilities, particularly as regulatory requirements, technological complexity and compliance costs continue to intensify across major markets.

As a result, contract manufacturing organisations are being integrated earlier into development programmes and retained for longer commercial partnerships, spanning late-stage clinical production through to full-scale commercial supply. This reflects a deliberate shift towards operational agility, enabling vaccine sponsors to scale capacity, rebalance portfolios and respond rapidly to public-health demand without committing significant capital to fixed infrastructure.

Consequently, the structural growth of outsourcing in the vaccine sector is being underpinned by capital efficiency considerations, reduced balance-sheet risk and the strategic imperative to shorten development and commercialisation timelines.

What would be the Impact of US Trade Tariffs on the Global Vaccine Contract Manufacturing Market?

US trade tariffs are likely to generate sustained cost pressures and prompt selective operational recalibration across the global vaccine contract manufacturing market, rather than a uniform industry-wide disruption. Tariffs on imported bioprocessing equipment, single-use consumables, process intermediates and certain specialised raw materials would increase manufacturing input costs, particularly for contract manufacturing organisations (CMOs) that rely on globally integrated supply chains, imported single-use technologies, and cross-border procurement of critical inputs such as filters, resins and sterile packaging components. In the near term, this is expected to affect pricing negotiations, programme timelines and margin visibility for both vaccine sponsors and manufacturing partners, with smaller CMOs and development-stage projects likely to experience greater cost pass-through than large-scale commercial programmes.

Over the medium to long term, tariff-related uncertainty is likely to accelerate structural shifts towards regional manufacturing localisation and supply-chain diversification, but the extent of relocation will vary by technology platform. Traditional protein-based and viral-vector manufacturing may see more regionalisation, whereas highly specialised platforms such as mRNA are likely to remain concentrated in a smaller number of advanced facilities due to technical complexity and capital intensity. Vaccine developers are expected to prioritise CMOs with domestic or tariff-shielded production footprints, stable access to critical single-use suppliers, and proven regulatory track records with the US Food and Drug Administration. In response, CMOs are likely to expand regional capacity, implement dual-sourcing strategies for key consumables, and invest in localised fill-finish infrastructure to reduce exposure to border frictions.

US-based manufacturers may benefit from reshoring incentives, public-private preparedness programmes and priority government procurement commitments, which could partially offset tariff-driven cost increases. By contrast, non-US CMOs are expected to pursue targeted US investments, joint ventures, or strategic partnerships with domestic players to maintain market access, rather than fully relocating production. Overall, tariffs are more likely to reshape supply-chain architecture and investment patterns in vaccine contract manufacturing than to materially constrain global supply in the short term.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the vaccine contract manufacturing market evolving?
  • What is driving and restraining the vaccine contract manufacturing market?
  • How will each vaccine contract manufacturing submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2036?
  • How will the market shares for each vaccine contract manufacturing submarket develop from 2026 to 2036?
  • What will be the main driver for the overall market from 2026 to 2036?
  • Will leading vaccine contract manufacturing markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2036 and which geographical region will lead the market in 2036?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the vaccine contract manufacturing projects for these leading companies?
  • How will the industry evolve during the period between 2026 and 2036? What are the implications of
  • vaccine contract manufacturing projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the vaccine contract manufacturing market?
  • Where is the vaccine contract manufacturing market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the vaccine contract manufacturing market today, and over the next 10 years:

  • Our 314-page report provides 115 tables and 180 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them - NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.
  • Forecasts to 2036 and other analyses reveal commercial prospects
  • In addition to revenue forecasting to 2036, our new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter's Five Forces Analysis, PEST Analysis and recent developments.

Segments Covered in the Report

  • Type
  • Subunit Vaccines
  • Live Attenuated Vaccines
  • Conjugate Vaccines
  • Inactivated Vaccines
  • Toxoid Vaccines
  • Viral Vector Vaccines
  • Recombinant Vector Vaccines
  • Other Vaccine Types
  • Process
  • Upstream Process
  • Downstream Process
  • End-use
  • Human Use
  • Veterinary
  • Operation
  • Preclinical
  • Clinical
  • Commercial
  • Company Size
  • Small Manufacturers
  • Mid-sized Manufacturers
  • Large Manufacturers
  • Very Large Manufacturers

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 19 leading national markets:

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • MEA
  • GCC
  • South Africa
  • Rest of MEA

The report also includes profiles for some of the leading companies in the Vaccine Contract Manufacturing Market, 2026 to 2036, with a focus on this segment of these companies' operations.

  • Leading companies and the potential for market growth
  • Ajinomoto Bio-Pharma
  • Batavia Biosciences B.V.
  • Bavarian Nordic
  • Catalent, Inc
  • Charles River Laboratories
  • Curia Global, Inc.
  • Emergent BioSolutions
  • FUJIFILM Holdings Corporation
  • ICON plc
  • IDT Biologika
  • Lonza
  • Recipharm AB
  • Richter-Helm BioLogics GmbH & Co. KG
  • WuXi Biologics

Overall world revenue for Vaccine Contract Manufacturing Market, 2026 to 2036 in terms of value the market will surpass US$3,900.0 million in 2026, our work calculates. We predict strong revenue growth through to 2036. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

  • How will the Vaccine Contract Manufacturing Market, 2026 to 2036 report help you?
  • In summary, our 310+ page report provides you with the following knowledge:
  • Revenue forecasts to 2036 for Vaccine Contract Manufacturing Market 2026 to 2036, with forecasts for Type, Process, End-use, Operation, Company Size, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2036 for five regional and 19 key national markets - See forecasts for the Vaccine Contract Manufacturing Market, 2026 to 2036 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 16 of the major companies involved in the Vaccine Contract Manufacturing Market, 2026 to 2036.
  • Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Show more
Product Code: PHA1378

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Vaccine Contract Manufacturing Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report Include:
  • 1.6 Who is This Report For?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
  • 3.3 Impact Analysis
    • 3.3.1 Market Driving Factors
      • 3.3.1.1 Growth in Infectious Diseases
      • 3.3.1.2 Stakeholder Cooperation Maximizes Manufacturing Capacity
      • 3.3.1.3 Advancements in Single-use and Modular Facilities
      • 3.3.1.4 CDMO Platform Bundling for mRNA and Viral-vector Tech
    • 3.3.2 Market Restraining Factors
      • 3.3.2.1 Escalating Biologics Grade Raw Materials Costs
      • 3.3.2.2 Regulatory Lag in Tech-Transfer Validation
      • 3.3.2.3 Cold Chain Gaps in Emerging Markets
    • 3.3.3 Market Opportunities
      • 3.3.3.1 New Vaccine Technologies
      • 3.3.3.2 Gene Based Vaccines
  • 3.4 U.S. Tariffs: What's the Impact on Global Vaccine Contract Manufacturing Market?
    • 3.4.1 Overview
    • 3.4.2 V-Shaped Recovery Scenario
    • 3.4.3 Why V-Shaped Recovery?
      • 3.4.3.1 Impact from Tariffs
      • 3.4.3.2 Market Dynamics and Demand Recovery
      • 3.4.3.3 Policy and Funding Support
      • 3.4.3.4 Timeframe for Recovery
    • 3.4.4 U-Shaped Recovery Scenario
      • 3.4.4.1 Why U-Shaped Recovery?
      • 3.4.4.2 Impact from Tariffs
      • 3.4.4.3 Market Dynamics and Demand Recovery
      • 3.4.4.4 Policy and Funding Support
      • 3.4.4.5 Timeframe for Recovery
    • 3.4.5 L Shaped Recovery Scenario
      • 3.4.5.1 Why L-Shaped Recovery?
      • 3.4.5.2 Impact from Tariffs
      • 3.4.5.3 Market Dynamics and Demand Recovery
      • 3.4.5.4 Policy and Funding Support
      • 3.4.5.5 Timeframe for Recovery
    • 3.4.6 What Strategic Considerations Should Clients Factor into Their Near-term (2026-2031) and Long-term (2026-2036) Planning?
    • 3.4.7 Impact of U.S. and China Trade War on Vaccine Contract Manufacturing Market
    • 3.4.8 How Might the Most Impacted Countries Experience Positive and Negative Effects Resulting from These Policy Changes?
  • 3.5 Porter's Five Forces Analysis
    • 3.5.1 Bargaining Power of Suppliers
    • 3.5.2 Bargaining Power of Buyers
    • 3.5.3 Competitive Rivalry
    • 3.5.4 Threat from Substitutes
    • 3.5.5 Threat of New Entrants
  • 3.6 PEST Analysis

4 Vaccine Contract Manufacturing Market Analysis by Type

  • 4.1 Key Findings
  • 4.2 Type Segment: Market Attractiveness Index
  • 4.3 Vaccine Contract Manufacturing Market Size Estimation and Forecast by Type
  • 4.4 Subunit Vaccines
    • 4.4.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 4.4.2 Market Share by Region, 2026 & 2036 (%)
  • 4.5 Live Attenuated Vaccines
    • 4.5.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 4.5.2 Market Share by Region, 2026 & 2036 (%)
  • 4.6 Conjugate Vaccines
    • 4.6.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 4.6.2 Market Share by Region, 2026 & 2036 (%)
  • 4.7 Inactivated Vaccines
    • 4.7.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 4.7.2 Market Share by Region, 2026 & 2036 (%)
  • 4.8 Toxoid Vaccines
    • 4.8.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 4.8.2 Market Share by Region, 2026 & 2036 (%)
  • 4.9 Viral Vector Vaccines
    • 4.9.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 4.9.2 Market Share by Region, 2026 & 2036 (%)
  • 4.10 Recombinant Vector Vaccines
    • 4.10.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 4.10.2 Market Share by Region, 2026 & 2036 (%)
  • 4.11 Other Vaccine Types
    • 4.11.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 4.11.2 Market Share by Region, 2026 & 2036 (%)

5 Vaccine Contract Manufacturing Market Analysis by Process

  • 5.1 Key Findings
  • 5.2 Process Segment: Market Attractiveness Index
  • 5.3 Vaccine Contract Manufacturing Market Size Estimation and Forecast by Process
  • 5.4 Upstream Process
    • 5.4.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 5.4.2 Market Share by Region, 2026 & 2036 (%)
  • 5.5 Downstream Process
    • 5.5.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 5.5.2 Market Share by Region, 2026 & 2036 (%)

6 Vaccine Contract Manufacturing Market Analysis by End-use

  • 6.1 Key Findings
  • 6.2 End-use Segment: Market Attractiveness Index
  • 6.3 Vaccine Contract Manufacturing Market Size Estimation and Forecast by End-use
  • 6.4 Human Use
    • 6.4.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 6.4.2 Market Share by Region, 2026 & 2036 (%)
  • 6.5 Veterinary
    • 6.5.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 6.5.2 Market Share by Region, 2026 & 2036 (%)

7 Vaccine Contract Manufacturing Market Analysis by Operation

  • 7.1 Key Findings
  • 7.2 Operation Segment: Market Attractiveness Index
  • 7.3 Vaccine Contract Manufacturing Market Size Estimation and Forecast by Operation
  • 7.4 Preclinical
    • 7.4.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 7.4.2 Market Share by Region, 2026 & 2036 (%)
  • 7.5 Clinical
    • 7.5.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 7.5.2 Market Share by Region, 2026 & 2036 (%)
  • 7.6 Commercial
    • 7.6.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 7.6.2 Market Share by Region, 2026 & 2036 (%)

8 Vaccine Contract Manufacturing Market Analysis by Company Size

  • 8.1 Key Findings
  • 8.2 Company Size Segment: Market Attractiveness Index
  • 8.3 Vaccine Contract Manufacturing Market Size Estimation and Forecast by Company Size
  • 8.4 Small Manufacturers
    • 8.4.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 8.4.2 Market Share by Region, 2026 & 2036 (%)
  • 8.5 Mid-sized Manufacturers
    • 8.5.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 8.5.2 Market Share by Region, 2026 & 2036 (%)
  • 8.6 Large Manufacturers
    • 8.6.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 8.6.2 Market Share by Region, 2026 & 2036 (%)
  • 8.7 Very Large Manufacturers
    • 8.7.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 8.7.2 Market Share by Region, 2026 & 2036 (%)

9 Vaccine Contract Manufacturing Market Analysis by Region

  • 9.1 Key Findings
  • 9.2 Regional Market Size Estimation and Forecast

10 North America Vaccine Contract Manufacturing Market Analysis

  • 10.1 Key Findings
  • 10.2 North America Vaccine Contract Manufacturing Market Attractiveness Index
  • 10.3 North America Vaccine Contract Manufacturing Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 10.4 North America Vaccine Contract Manufacturing Market Size Estimation and Forecast by Country
  • 10.5 North America Vaccine Contract Manufacturing Market Size Estimation and Forecast by Type
  • 10.6 North America Vaccine Contract Manufacturing Market Size Estimation and Forecast by Process
  • 10.7 North America Vaccine Contract Manufacturing Market Size Estimation and Forecast by End-use
  • 10.8 North America Vaccine Contract Manufacturing Market Size Estimation and Forecast by Operation
  • 10.9 North America Vaccine Contract Manufacturing Market Size Estimation and Forecast by Company Size
  • 10.10 U.S. Vaccine Contract Manufacturing Market Analysis
  • 10.11 Canada Vaccine Contract Manufacturing Market Analysis

11 Europe Vaccine Contract Manufacturing Market Analysis

  • 11.1 Key Findings
  • 11.2 Europe Vaccine Contract Manufacturing Market Attractiveness Index
  • 11.3 Europe Vaccine Contract Manufacturing Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 11.4 Europe Vaccine Contract Manufacturing Market Size Estimation and Forecast by Country
  • 11.5 Europe Vaccine Contract Manufacturing Market Size Estimation and Forecast by Type
  • 11.6 Europe Vaccine Contract Manufacturing Market Size Estimation and Forecast by Process
  • 11.7 Europe Vaccine Contract Manufacturing Market Size Estimation and Forecast by End-use
  • 11.8 Europe Vaccine Contract Manufacturing Market Size Estimation and Forecast by Operation
  • 11.9 Europe Vaccine Contract Manufacturing Market Size Estimation and Forecast by Company Size
  • 11.10 Germany Vaccine Contract Manufacturing Market Analysis
  • 11.11 UK Vaccine Contract Manufacturing Market Analysis
  • 11.12 France Vaccine Contract Manufacturing Market Analysis
  • 11.13 Italy Vaccine Contract Manufacturing Market Analysis
  • 11.14 Spain Vaccine Contract Manufacturing Market Analysis
  • 11.15 Rest of Europe Vaccine Contract Manufacturing Market Analysis

12 Asia Pacific Vaccine Contract Manufacturing Market Analysis

  • 12.1 Key Findings
  • 12.2 Asia Pacific Vaccine Contract Manufacturing Market Attractiveness Index
  • 12.3 Asia Pacific Vaccine Contract Manufacturing Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 12.4 Asia Pacific Vaccine Contract Manufacturing Market Size Estimation and Forecast by Country
  • 12.5 Asia Pacific Vaccine Contract Manufacturing Market Size Estimation and Forecast by Type
  • 12.6 Asia Pacific Vaccine Contract Manufacturing Market Size Estimation and Forecast by Process
  • 12.7 Asia Pacific Vaccine Contract Manufacturing Market Size Estimation and Forecast by End-use
  • 12.8 Asia Pacific Vaccine Contract Manufacturing Market Size Estimation and Forecast by Operation
  • 12.9 Asia Pacific Vaccine Contract Manufacturing Market Size Estimation and Forecast by Company Size
  • 12.10 Japan Vaccine Contract Manufacturing Market Analysis
  • 12.11 China Vaccine Contract Manufacturing Market Analysis
  • 12.12 India Vaccine Contract Manufacturing Market Analysis
  • 12.13 Australia Vaccine Contract Manufacturing Market Analysis
  • 12.14 Rest of Asia Pacific Vaccine Contract Manufacturing Market Analysis

13 Latin America Vaccine Contract Manufacturing Market Analysis

  • 13.1 Key Findings
  • 13.2 Latin America Vaccine Contract Manufacturing Market Attractiveness Index
  • 13.3 Latin America Vaccine Contract Manufacturing Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 13.4 Latin America Vaccine Contract Manufacturing Market Size Estimation and Forecast by Country
  • 13.5 Latin America Vaccine Contract Manufacturing Market Size Estimation and Forecast by Type
  • 13.6 Latin America Vaccine Contract Manufacturing Market Size Estimation and Forecast by Process
  • 13.7 Latin America Vaccine Contract Manufacturing Market Size Estimation and Forecast by End-use
  • 13.8 Latin America Vaccine Contract Manufacturing Market Size Estimation and Forecast by Operation
  • 13.9 Latin America Vaccine Contract Manufacturing Market Size Estimation and Forecast by Company Size
  • 13.10 Brazil Vaccine Contract Manufacturing Market Analysis
  • 13.11 Mexico Vaccine Contract Manufacturing Market Analysis
  • 13.12 Rest of Latin America Vaccine Contract Manufacturing Market Analysis

14 MEA Vaccine Contract Manufacturing Market Analysis

  • 14.1 Key Findings
  • 14.2 MEA Vaccine Contract Manufacturing Market Attractiveness Index
  • 14.3 MEA Vaccine Contract Manufacturing Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 14.4 MEA Vaccine Contract Manufacturing Market Size Estimation and Forecast by Country
  • 14.5 MEA Vaccine Contract Manufacturing Market Size Estimation and Forecast by Type
  • 14.6 MEA Vaccine Contract Manufacturing Market Size Estimation and Forecast by Process
  • 14.7 MEA Vaccine Contract Manufacturing Market Size Estimation and Forecast by End-use
  • 14.8 MEA Vaccine Contract Manufacturing Market Size Estimation and Forecast by Operation
  • 14.9 MEA Vaccine Contract Manufacturing Market Size Estimation and Forecast by Company Size
  • 14.10 GCC Vaccine Contract Manufacturing Market Analysis
  • 14.11 South Africa Vaccine Contract Manufacturing Market Analysis
  • 14.12 Rest of MEA Vaccine Contract Manufacturing Market Analysis

15 Company Profiles

  • 15.1 Catalent, Inc
    • 15.1.1 Company Snapshot
    • 15.1.2 Company Overview
    • 15.1.3 Financial Analysis
      • 15.1.3.1 Net Revenue, 2020-2024
      • 15.1.3.2 Regional Market Shares, 2024
      • 15.1.3.3 Business Segment Market Shares, 2024
    • 15.1.4 Service Benchmarking
    • 15.1.5 Strategic Outlook
  • 15.2 Emergent BioSolutions
    • 15.2.1 Company Snapshot
    • 15.2.2 Company Overview
    • 15.2.3 Financial Analysis
      • 15.2.3.1 Net Revenue, 2020-2024
    • 15.2.4 Service Benchmarking
    • 15.2.5 Strategic Outlook
  • 15.3 Ajinomoto Bio-Pharma
    • 15.3.1 Company Snapshot
    • 15.3.2 Company Overview
    • 15.3.3 Financial Analysis
      • 15.3.3.1 Net Revenue, 2020-2024
      • 15.3.3.2 R&D, 2020-2024
      • 15.3.3.3 Business Segment Market Shares, 2024
    • 15.3.4 Service Benchmarking
    • 15.3.5 Strategic Outlook
  • 15.4 Lonza
    • 15.4.1 Company Snapshot
    • 15.4.2 Company Overview
    • 15.4.3 Financial Analysis
      • 15.4.3.1 Net Revenue, 2020-2024
      • 15.4.3.2 R&D, 2020-2024
      • 15.4.3.3 Regional Market Shares, 2024
      • 15.4.3.4 Business Segment Market Shares, 2024
    • 15.4.4 Service Benchmarking
    • 15.4.5 Strategic Outlook
  • 15.5 Curia Global, Inc.
    • 15.5.1 Company Snapshot
    • 15.5.2 Company Overview
    • 15.5.3 Service Benchmarking
    • 15.5.4 Strategic Outlook
  • 15.6 WuXi Biologics
    • 15.6.1 Company Snapshot
    • 15.6.2 Company Overview
    • 15.6.3 Financial Analysis
      • 15.6.3.1 Net Revenue, 2020-2024
      • 15.6.3.2 Regional Market Shares, 2024
      • 15.6.3.3 Business Segment Market Shares, 2024
    • 15.6.4 Service Benchmarking
    • 15.6.5 Strategic Outlook
  • 15.7 FUJIFILM Holdings Corporation
    • 15.7.1 Company Snapshot
    • 15.7.2 Company Overview
    • 15.7.3 Service Benchmarking
  • 15.8 Recipharm AB
    • 15.8.1 Company Snapshot
    • 15.8.2 Company Overview
    • 15.8.3 Service Benchmarking
    • 15.8.4 Strategic Outlook
  • 15.9 Richter-Helm BioLogics GmbH & Co. KG
    • 15.9.1 Company Snapshot
    • 15.9.2 Company Overview
    • 15.9.3 Service Benchmarking
  • 15.10 Bavarian Nordic
    • 15.10.1 Company Snapshot
    • 15.10.2 Company Overview
    • 15.10.3 Service Benchmarking
    • 15.10.4 Strategic Outlook
  • 15.11 Charles River Laboratories
    • 15.11.1 Company Snapshot
    • 15.11.2 Company Overview
    • 15.11.3 Financial Analysis
      • 15.11.3.1 Net Revenue, 2020-2024
      • 15.11.3.2 Regional Market Shares, 2024
    • 15.11.4 Service Benchmarking
    • 15.11.5 Strategic Outlook
  • 15.12 ICON plc
    • 15.12.1 Company Snapshot
    • 15.12.2 Company Overview
    • 15.12.3 Financial Analysis
      • 15.12.3.1 Net Revenue, 2020-2024
      • 15.12.3.2 Regional Market Shares, 2024
    • 15.12.4 Service Benchmarking
  • 15.13 Batavia Biosciences B.V.
    • 15.13.1 Company Snapshot
    • 15.13.2 Company Overview
    • 15.13.3 Service Benchmarking
  • 15.14 IDT Biologika
    • 15.14.1 Company Snapshot
    • 15.14.2 Company Overview
    • 15.14.3 Service Benchmarking

16 Conclusion and Recommendations

  • 16.1 Concluding Remarks from Visiongain
  • 16.2 Recommendations for Market Players
Show more
Product Code: PHA1378

List of Tables

  • Table 1 Vaccine Contract Manufacturing Market Snapshot, 2026 & 2036 (US$ million, CAGR %)
  • Table 2 Vaccine Contract Manufacturing Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%): "V" Shaped Recovery
  • Table 3 Vaccine Contract Manufacturing Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%): "U" Shaped Recovery
  • Table 4 Vaccine Contract Manufacturing Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%): "L" Shaped Recovery
  • Table 5 Vaccine Contract Manufacturing Market Forecast by Type, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 6 Subunit Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 7 Live Attenuated Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 8 Conjugate Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 9 Inactivated Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 10 Toxoid Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 11 Viral Vector Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 12 Recombinant Vector Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 13 Other Vaccine Types Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 14 North America Vaccine Contract Manufacturing Market Forecast by Process, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 15 Upstream Process Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 16 Downstream Process Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 17 North America Vaccine Contract Manufacturing Market Forecast by End-use, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 18 Human Use Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 19 Veterinary Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 20 North America Vaccine Contract Manufacturing Market Forecast by Operation, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 21 Preclinical Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 22 Clinical Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 23 Commercial Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 24 Vaccine Contract Manufacturing Market Forecast by Company Size, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 25 Small Manufacturers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 26 Mid-sized Manufacturers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 27 Large Manufacturers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 28 Very Large Manufacturers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 29 Vaccine Contract Manufacturing Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 30 North America Vaccine Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 31 North America Vaccine Contract Manufacturing Market Forecast by Type, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 32 North America Vaccine Contract Manufacturing Market Forecast by Process, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 33 North America Vaccine Contract Manufacturing Market Forecast by End-use, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 34 North America Vaccine Contract Manufacturing Market Forecast by Operation, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 35 North America Vaccine Contract Manufacturing Market Forecast by Company Size, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 36 U.S. Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 37 Canada Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 38 Europe Vaccine Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 39 Europe Vaccine Contract Manufacturing Market Forecast by Type, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 40 Europe Vaccine Contract Manufacturing Market Forecast by Process, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 41 Europe Vaccine Contract Manufacturing Market Forecast by End-use, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 42 Europe Vaccine Contract Manufacturing Market Forecast by Operation, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 43 Europe Vaccine Contract Manufacturing Market Forecast by Company Size, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 44 Germany Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 45 UK Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 46 France Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 47 Italy Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 48 Spain Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 49 Rest of Europe Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 50 Asia Pacific Vaccine Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 51 Asia Pacific Vaccine Contract Manufacturing Market Forecast by Type, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 52 Asia Pacific Vaccine Contract Manufacturing Market Forecast by Process, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 53 Asia Pacific Vaccine Contract Manufacturing Market Forecast by End-use, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 54 Asia Pacific Vaccine Contract Manufacturing Market Forecast by Operation, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 55 Asia Pacific Vaccine Contract Manufacturing Market Forecast by Company Size, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 56 Japan Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 57 China Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 58 India Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 59 Australia Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 60 Rest of Asia Pacific Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 61 Latin America Vaccine Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 62 Latin America Vaccine Contract Manufacturing Market Forecast by Type, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 63 Latin America Vaccine Contract Manufacturing Market Forecast by Process, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 64 Latin America Vaccine Contract Manufacturing Market Forecast by End-use, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 65 Latin America Vaccine Contract Manufacturing Market Forecast by Operation, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 66 Latin America Vaccine Contract Manufacturing Market Forecast by Company Size, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 67 Brazil Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 68 Mexico Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 69 Rest of Latin America Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 70 MEA Vaccine Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 71 MEA Vaccine Contract Manufacturing Market Forecast by Type, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 72 MEA Vaccine Contract Manufacturing Market Forecast by Process, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 73 MEA Vaccine Contract Manufacturing Market Forecast by End-use, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 74 MEA Vaccine Contract Manufacturing Market Forecast by Operation, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 75 MEA Vaccine Contract Manufacturing Market Forecast by Company Size, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 76 GCC Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 77 South Africa Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 78 Rest of MEA Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 79 Catalent, Inc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 80 Catalent, Inc: Service Benchmarking
  • Table 81 Catalent, Inc: Strategic Outlook
  • Table 82 Emergent BioSolutions: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 83 Emergent BioSolutions: Service Benchmarking
  • Table 84 Emergent BioSolutions: Strategic Outlook
  • Table 85 Ajinomoto Bio-Pharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 86 Ajinomoto Bio-Pharma: Service Benchmarking
  • Table 87 Ajinomoto Bio-Pharma: Strategic Outlook
  • Table 88 Lonza: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 89 Lonza: Service Benchmarking
  • Table 90 Lonza: Strategic Outlook
  • Table 91 Curia Global, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 92 Curia Global Inc.: Service Benchmarking
  • Table 93 Curia Global Inc.: Strategic Outlook
  • Table 94 WuXi Biologics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 95 WuXi Biologics: Service Benchmarking
  • Table 96 WuXi Biologics: Strategic Outlook
  • Table 97 FUJIFILM Holdings Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 98 FUJIFILM Holdings Corporation: Service Benchmarking
  • Table 99 Recipharm AB: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 100 Recipharm AB: Service Benchmarking
  • Table 101 Recipharm AB: Strategic Outlook
  • Table 102 Richter-Helm BioLogics GmbH & Co. KG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 103 Richter-Helm BioLogics GmbH & Co. KG: Service Benchmarking
  • Table 104 Bavarian Nordic: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 105 Bavarian Nordic: Service Benchmarking
  • Table 106 Bavarian Nordic: Strategic Outlook
  • Table 107 Charles River Laboratories: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 108 Charles River Laboratories: Service Benchmarking
  • Table 109 Charles River Laboratories: Strategic Outlook
  • Table 110 ICON plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 111 ICON plc: Service Benchmarking
  • Table 112 Batavia Biosciences B.V.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 113 Batavia Biosciences B.V.: Service Benchmarking
  • Table 114 IDT Biologika: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 115 IDT Biologika: Service Benchmarking

List of Figures

  • Figure 1 Vaccine Contract Manufacturing Market Segmentation
  • Figure 2 Vaccine Contract Manufacturing Market by Type: Market Attractiveness Index
  • Figure 3 Vaccine Contract Manufacturing Market by Process: Market Attractiveness Index
  • Figure 4 Vaccine Contract Manufacturing Market by End-use: Market Attractiveness Index
  • Figure 5 Vaccine Contract Manufacturing Market by Operation: Market Attractiveness Index
  • Figure 6 Vaccine Contract Manufacturing Market by Company Size: Market Attractiveness Index
  • Figure 7 Vaccine Contract Manufacturing Market Attractiveness Index by Region
  • Figure 8 Vaccine Contract Manufacturing Market: Market Dynamics
  • Figure 9 Vaccine Contract Manufacturing Market: Impact Analysis
  • Figure 10 Vaccine Contract Manufacturing Market by Region, 2026-2036 (US$ Million, AGR %), Tariff Impact: V-Shaped Recovery Scenario
  • Figure 11 Vaccine Contract Manufacturing Market by Region, 2026-2036 (US$ Million, AGR %), Tariff Impact: U-Shaped Recovery Scenario
  • Figure 12 Vaccine Contract Manufacturing Market by Region, 2026-2036 (US$ Million, AGR %), Tariff Impact: L-Shaped Recovery Scenario
  • Figure 13 Short Term & Long Term Planning
  • Figure 14 Impact of U.S. and China Trade War
  • Figure 15 Most Impacted Countries
  • Figure 16 Vaccine Contract Manufacturing Market: Porter's Five Forces Analysis
  • Figure 17 Vaccine Contract Manufacturing Market: PEST Analysis
  • Figure 18 Vaccine Contract Manufacturing Market Attractiveness Index by Type
  • Figure 19 Vaccine Contract Manufacturing Market Forecast by Type, 2026-2036 (US$ Million, AGR %)
  • Figure 20 Vaccine Contract Manufacturing Market Share Forecast by Type, 2026, 2031, 2036 (%)
  • Figure 21 Subunit Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 22 Subunit Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 23 Live Attenuated Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 24 Live Attenuated Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 25 Conjugate Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 26 Conjugate Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 27 Inactivated Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 28 Inactivated Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 29 Toxoid Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 30 Toxoid Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 31 Viral Vector Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 32 Viral Vector Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 33 Recombinant Vector Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 34 Recombinant Vector Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 35 Other Vaccine Types Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 36 Other Vaccine Types Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 37 Vaccine Contract Manufacturing Market Attractiveness Index by Type
  • Figure 38 Vaccine Contract Manufacturing Market Forecast by Process, 2026-2036 (US$ Million, AGR %)
  • Figure 39 Vaccine Contract Manufacturing Market Share Forecast by Process, 2026, 2031, 2036 (%)
  • Figure 40 Upstream Process Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 41 Upstream Process Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 42 Downstream Process Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 43 Downstream Process Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 44 Vaccine Contract Manufacturing Market Attractiveness Index by End-use
  • Figure 45 Vaccine Contract Manufacturing Market Forecast by End-use, 2026-2036 (US$ Million, AGR %)
  • Figure 46 Vaccine Contract Manufacturing Market Share Forecast by End-use, 2026, 2031, 2036 (%)
  • Figure 47 Human Use Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 48 Human Use Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 49 Veterinary Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 50 Veterinary Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 51 Vaccine Contract Manufacturing Market Attractiveness Index by Operation
  • Figure 52 Vaccine Contract Manufacturing Market Forecast by Operation, 2026-2036 (US$ Million, AGR %)
  • Figure 53 Vaccine Contract Manufacturing Market Share Forecast by Operation, 2026, 2031, 2036 (%)
  • Figure 54 Preclinical Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 55 Preclinical Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 56 Clinical Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 57 Clinical Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 58 Commercial Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 59 Commercial Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 60 Vaccine Contract Manufacturing Market Attractiveness Index by Company Size
  • Figure 61 Vaccine Contract Manufacturing Market Forecast by Company Size, 2026-2036 (US$ Million, AGR %)
  • Figure 62 Vaccine Contract Manufacturing Market Share Forecast by Company Size, 2026, 2031, 2036 (%)
  • Figure 63 Small Manufacturers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 64 Small Manufacturers Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 65 Mid-sized Manufacturers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 66 Mid-sized Manufacturers Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 67 Large Manufacturers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 68 Large Manufacturers Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 69 Very Large Manufacturers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 70 Very Large Manufacturers Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 71 Vaccine Contract Manufacturing Market Forecast by Region 2026, 2031, 2036 (Revenue, CAGR%)
  • Figure 72 Vaccine Contract Manufacturing Market Share Forecast by Region 2026, 2031, 2036 (%)
  • Figure 73 Vaccine Contract Manufacturing Market by Region, 2026-2036 (US$ Mn)
  • Figure 74 North America Vaccine Contract Manufacturing Market Attractiveness Index
  • Figure 75 North America Vaccine Contract Manufacturing Market by Region, 2026, 2031 & 2036 (US$ Million)
  • Figure 76 North America Vaccine Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 77 North America Vaccine Contract Manufacturing Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 78 North America Vaccine Contract Manufacturing Market Forecast by Type, 2026-2036 (US$ Million, AGR %)
  • Figure 79 North America Vaccine Contract Manufacturing Market Share Forecast by Type, 2026 & 2036 (%)
  • Figure 80 North America Vaccine Contract Manufacturing Market Forecast by Process, 2026-2036 (US$ Million, AGR %)
  • Figure 81 North America Vaccine Contract Manufacturing Market Share Forecast by Process, 2026 & 2036 (%)
  • Figure 82 North America Vaccine Contract Manufacturing Market Forecast by End-use, 2026-2036 (US$ Million, AGR %)
  • Figure 83 North America Vaccine Contract Manufacturing Market Share Forecast by End-use, 2026 & 2036 (%)
  • Figure 84 North America Vaccine Contract Manufacturing Market Forecast by Operation, 2026-2036 (US$ Million, AGR %)
  • Figure 85 North America Vaccine Contract Manufacturing Market Share Forecast by Operation, 2026 & 2036 (%)
  • Figure 86 North America Vaccine Contract Manufacturing Market Forecast by Company Size, 2026-2036 (US$ Million, AGR %)
  • Figure 87 North America Vaccine Contract Manufacturing Market Share Forecast by Company Size, 2026 & 2036 (%)
  • Figure 88 U.S. Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 89 Canada Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 90 Europe Vaccine Contract Manufacturing Market Attractiveness Index
  • Figure 91 Europe Vaccine Contract Manufacturing Market by Region, 2026, 2031 & 2036 (US$ Million)
  • Figure 92 Europe Vaccine Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 93 Europe Vaccine Contract Manufacturing Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 94 Europe Vaccine Contract Manufacturing Market Forecast by Type, 2026-2036 (US$ Million, AGR %)
  • Figure 95 Europe Vaccine Contract Manufacturing Market Share Forecast by Type, 2026 & 2036 (%)
  • Figure 96 Europe Vaccine Contract Manufacturing Market Forecast by Process, 2026-2036 (US$ Million, AGR %)
  • Figure 97 Europe Vaccine Contract Manufacturing Market Share Forecast by Process, 2026 & 2036 (%)
  • Figure 98 Europe Vaccine Contract Manufacturing Market Forecast by End-use, 2026-2036 (US$ Million, AGR %)
  • Figure 99 Europe Vaccine Contract Manufacturing Market Share Forecast by End-use, 2026 & 2036 (%)
  • Figure 100 Europe Vaccine Contract Manufacturing Market Forecast by Operation, 2026-2036 (US$ Million, AGR %)
  • Figure 101 Europe Vaccine Contract Manufacturing Market Share Forecast by Operation, 2026 & 2036 (%)
  • Figure 102 Europe Vaccine Contract Manufacturing Market Forecast by Company Size, 2026-2036 (US$ Million, AGR %)
  • Figure 103 Europe Vaccine Contract Manufacturing Market Share Forecast by Company Size, 2026 & 2036 (%)
  • Figure 104 Germany Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 105 UK Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 106 France Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 107 Italy Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 108 Spain Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 109 Rest of Europe Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 110 Asia Pacific Vaccine Contract Manufacturing Market Attractiveness Index
  • Figure 111 Asia Pacific Vaccine Contract Manufacturing Market by Region, 2026, 2031 & 2036 (US$ Million)
  • Figure 112 Asia Pacific Vaccine Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 113 Asia Pacific Vaccine Contract Manufacturing Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 114 Asia Pacific Vaccine Contract Manufacturing Market Forecast by Type, 2026-2036 (US$ Million, AGR %)
  • Figure 115 Asia Pacific Vaccine Contract Manufacturing Market Share Forecast by Type, 2026 & 2036 (%)
  • Figure 116 Asia Pacific Vaccine Contract Manufacturing Market Forecast by Process, 2026-2036 (US$ Million, AGR %)
  • Figure 117 Asia Pacific Vaccine Contract Manufacturing Market Share Forecast by Process, 2026 & 2036 (%)
  • Figure 118 Asia Pacific Vaccine Contract Manufacturing Market Forecast by End-use, 2026-2036 (US$ Million, AGR %)
  • Figure 119 Asia Pacific Vaccine Contract Manufacturing Market Share Forecast by End-use, 2026 & 2036 (%)
  • Figure 120 Asia Pacific Vaccine Contract Manufacturing Market Forecast by Operation, 2026-2036 (US$ Million, AGR %)
  • Figure 121 Asia Pacific Vaccine Contract Manufacturing Market Share Forecast by Operation, 2026 & 2036 (%)
  • Figure 122 Asia Pacific Vaccine Contract Manufacturing Market Forecast by Company Size, 2026-2036 (US$ Million, AGR %)
  • Figure 123 Asia Pacific Vaccine Contract Manufacturing Market Share Forecast by Company Size, 2026 & 2036 (%)
  • Figure 124 Japan Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 125 China Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 126 India Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 127 Australia Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 128 Rest of Asia Pacific Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 129 Latin America Vaccine Contract Manufacturing Market Attractiveness Index
  • Figure 130 Latin America Vaccine Contract Manufacturing Market by Region, 2026, 2031 & 2036 (US$ Million)
  • Figure 131 Latin America Vaccine Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 132 Latin America Vaccine Contract Manufacturing Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 133 Latin America Vaccine Contract Manufacturing Market Forecast by Type, 2026-2036 (US$ Million, AGR %)
  • Figure 134 Latin America Vaccine Contract Manufacturing Market Share Forecast by Type, 2026 & 2036 (%)
  • Figure 135 Latin America Vaccine Contract Manufacturing Market Forecast by Process, 2026-2036 (US$ Million, AGR %)
  • Figure 136 Latin America Vaccine Contract Manufacturing Market Share Forecast by Process, 2026 & 2036 (%)
  • Figure 137 Latin America Vaccine Contract Manufacturing Market Forecast by End-use, 2026-2036 (US$ Million, AGR %)
  • Figure 138 Latin America Vaccine Contract Manufacturing Market Share Forecast by End-use, 2026 & 2036 (%)
  • Figure 139 Latin America Vaccine Contract Manufacturing Market Forecast by Operation, 2026-2036 (US$ Million, AGR %)
  • Figure 140 Latin America Vaccine Contract Manufacturing Market Share Forecast by Operation, 2026 & 2036 (%)
  • Figure 141 Latin America Vaccine Contract Manufacturing Market Forecast by Company Size, 2026-2036 (US$ Million, AGR %)
  • Figure 142 Latin America Vaccine Contract Manufacturing Market Share Forecast by Company Size, 2026 & 2036 (%)
  • Figure 143 Brazil Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 144 Mexico Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 145 Rest of Latin America Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 146 MEA Vaccine Contract Manufacturing Market Attractiveness Index
  • Figure 147 MEA Vaccine Contract Manufacturing Market by Region, 2026, 2031 & 2036 (US$ Million)
  • Figure 148 MEA Vaccine Contract Manufacturing Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 149 MEA Vaccine Contract Manufacturing Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 150 MEA Vaccine Contract Manufacturing Market Forecast by Type, 2026-2036 (US$ Million, AGR %)
  • Figure 151 MEA Vaccine Contract Manufacturing Market Share Forecast by Type, 2026 & 2036 (%)
  • Figure 152 MEA Vaccine Contract Manufacturing Market Forecast by Process, 2026-2036 (US$ Million, AGR %)
  • Figure 153 MEA Vaccine Contract Manufacturing Market Share Forecast by Process, 2026 & 2036 (%)
  • Figure 154 MEA Vaccine Contract Manufacturing Market Forecast by End-use, 2026-2036 (US$ Million, AGR %)
  • Figure 155 MEA Vaccine Contract Manufacturing Market Share Forecast by End-use, 2026 & 2036 (%)
  • Figure 156 MEA Vaccine Contract Manufacturing Market Forecast by Operation, 2026-2036 (US$ Million, AGR %)
  • Figure 157 MEA Vaccine Contract Manufacturing Market Share Forecast by Operation, 2026 & 2036 (%)
  • Figure 158 MEA Vaccine Contract Manufacturing Market Forecast by Company Size, 2026-2036 (US$ Million, AGR %)
  • Figure 159 MEA Vaccine Contract Manufacturing Market Share Forecast by Company Size, 2026 & 2036 (%)
  • Figure 160 GCC Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 161 South Africa Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 162 Rest of MEA Vaccine Contract Manufacturing Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 163 Catalent, Inc: Net Revenue, 2020-2024 (US$ Million, AGR%)
  • Figure 164 Catalent, Inc: Regional Market Shares, 2024
  • Figure 165 Catalent, Inc: Business Segment Market Shares, 2024
  • Figure 166 Emergent BioSolutions: Net Revenue, 2020-2024 (US$ Million, AGR%)
  • Figure 167 Ajinomoto Bio-Pharma: Net Revenue, 2020-2024 (US$ Million, AGR%)
  • Figure 168 Ajinomoto Bio-Pharma: R&D, 2020-2024 (US$ Million, AGR%)
  • Figure 169 Ajinomoto Bio-Pharma: Business Segment Market Shares, 2024
  • Figure 170 Lonza: Net Revenue, 2020-2024 (US$ Million, AGR%)
  • Figure 171 Lonza: R&D, 2020-2024 (US$ Million, AGR%)
  • Figure 172 Lonza: Regional Market Shares, 2024
  • Figure 173 Lonza: Business Segment Market Shares, 2024
  • Figure 174 WuXi Biologics: Net Revenue, 2020-2024 (US$ Million, AGR%)
  • Figure 175 WuXi Biologics: Regional Market Shares, 2024
  • Figure 176 WuXi Biologics: Business Segment Market Shares, 2024
  • Figure 177 Charles River Laboratories: Net Revenue, 2020-2024 (US$ Million, AGR%)
  • Figure 178 Charles River Laboratories: Regional Market Shares, 2024
  • Figure 179 ICON plc: Net Revenue, 2020-2024 (US$ Million, AGR%)
  • Figure 180 ICON plc: Regional Market Shares, 2024
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!